Pushko Peter, Tretyakova Irina, Hidajat Rachmat, Zsak Aniko, Chrzastek Klaudia, Tumpey Terrence M, Kapczynski Darrell R
Medigen, Inc., 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA.
Medigen, Inc., 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA.
Virology. 2017 Jan 15;501:176-182. doi: 10.1016/j.virol.2016.12.001. Epub 2016 Dec 6.
Avian influenza (AI) viruses circulating in wild birds pose a serious threat to public health. Human and veterinary vaccines against AI subtypes are needed. Here we prepared triple-subtype VLPs that co-localized H5, H7 and H9 antigens derived from H5N1, H7N3 and H9N2 viruses. VLPs also contained influenza N1 neuraminidase and retroviral gag protein. The H5/H7/H9/N1/gag VLPs were prepared using baculovirus expression. Biochemical, functional and antigenic characteristics were determined including hemagglutination and neuraminidase enzyme activities. VLPs were further evaluated in a chicken AI challenge model for safety, immunogenicity and protective efficacy against heterologous AI viruses including H5N2, H7N3 and H9N2 subtypes. All vaccinated birds survived challenges with H5N2 and H7N3 highly pathogenic AI (HPAI) viruses, while all controls died. Immune response was also detectable after challenge with low pathogenicity AI (LPAI) H9N2 virus suggesting that H5/H7/H9/N1/gag VLPs represent a promising approach for the development of broadly protective AI vaccine.
野生鸟类中传播的禽流感(AI)病毒对公众健康构成严重威胁。需要针对AI亚型的人用和兽用疫苗。在此,我们制备了共定位源自H5N1、H7N3和H9N2病毒的H5、H7和H9抗原的三价亚型病毒样颗粒(VLPs)。VLPs还包含流感N1神经氨酸酶和逆转录病毒gag蛋白。H5/H7/H9/N1/gag VLPs采用杆状病毒表达制备。测定了其生化、功能和抗原特性,包括血凝和神经氨酸酶活性。在鸡AI攻毒模型中进一步评估了VLPs对包括H5N2、H7N3和H9N2亚型在内的异源AI病毒的安全性、免疫原性和保护效力。所有接种疫苗的鸡在受到H5N2和H7N3高致病性AI(HPAI)病毒攻击后存活,而所有对照鸡死亡。在用低致病性AI(LPAI)H9N2病毒攻击后也可检测到免疫反应,这表明H5/H7/H9/N1/gag VLPs是开发具有广泛保护作用的AI疫苗的一种有前景的方法。